Gyrus buying ENT business from S&N

7 May 2001

Gyrus Group of the UK is to acquire the ear, nose and throat devicesdivision from Smith & Nephew for $93 million in cash, $75 million of which will be payable once the deal closes. This is due to take place in early June, with the remainder to be paid by January 2003. The ENT business, based in Tennessee, USA, achieed turnover of around $42 million in 2000 and its products are sold in over 60 countries.

....and acquiring Somnus for $55.7 million

Gyrus also announced that it has agreed to buy the US Nasdaq-listed firm Somnus Medical Technologies, which develops medical devices for minimally-invasive surgery, for around $55.7 million or $3.11 per share. The latter's sales last year reached just over $12 million. In order to finance its spending spree, Gyrus is looking to raise L100 million ($143 million) in an offer of new shares, underwritten by broker WestLB Panmure. The company has also raised some L7.5 million from West Equity Bridge Finance.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight